Alain Valdivia

Alain Valdivia

Auto-generated profile, based on publicly available information

Alain Valdivia

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy University of North Carolina, Chapel Hill, North Carolina

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2021 in Science Advances
Verified
Journal Article
Open access
EOEdikan A. Ogunnaike
Edikan A. Ogunnaike
AVAlain Valdivia
Alain Valdivia
MYMostafa Yazdimamaghani
Mostafa Yazdimamaghani
ELErnesto Leon
Ernesto Leon
SNSeema Nandi
Seema Nandi
GDGianpietro Dotti
Gianpietro Dotti
In situ fibrin gel promotes the survival and the biodistribution of CAR-T cells, eliminating residual GBM cells after surgery.

11 June 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
WJWulin Jiang
Wulin Jiang
Yuchen YangYuchen Yang
Yuchen Yang
AMAlison R. Mercer-Smith
Alison R. Mercer-Smith
AVAlain Valdivia
Alain Valdivia
Juli BagóJuli Bagó
Juli Bagó
SHShawn D. Hingtgen
Shawn D. Hingtgen
Enhanced induced neural stem cell therapy shows superior efficacy in treating triple-negative breast cancer brain metastases.

22 October 2025 in bioRxiv
Verified
Preprint
Open access
HKHumeyra Kaanoglu
Humeyra Kaanoglu
YAYasemin Kubra Akyel
Yasemin Kubra Akyel
AAAdebimpe Adefolaju
Adebimpe Adefolaju
AVAlain Valdivia
Alain Valdivia
DHDominique Higgins
Dominique Higgins
ASAziz None Sancar
Aziz None Sancar
Glioblastoma (GBM) is the most aggressive malignant primary brain tumor in adults, with incidence peaking in later life. It is commonly treated with surgery followed by administration of ionizing radiation and the DNA alkylating agent temozolomide (TMZ). Even though this regimen confers some progression-free survival, there is essentially no cure with the median survival with the standard of care being about 12 months. Currently, several alternative approaches are being developed to improve upon this outcome. We have already shown EdU alone effectively treats GBM, and we now study efficacy of TMZ+EdU combination therapy. TMZ+EdU significantly improves antitumor efficacy compared to either single-agent therapy against GBM cell lines in vitro , against three different orthotopic GBM xenograft models, and against passage-zero patient GBM tumor tissues engrafted within an organotypic brain slice culture (OBSC)-based platform. Together, these data suggest that EdU could be effective alongside standard of care TMZ in patients with GBM. STATEMENT OF SIGNIFICANCE (50-WORD): By simultaneously engaging distinct DNA repair pathways, combination of TMZ and EdU produced unprecedented survival benefits and synergistic effects in preclinical GBM models, offering a promising new avenue in the treatment of GBM.

16 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AVAlain Valdivia
Alain Valdivia
AAAdebimpe Adefolaju
Adebimpe Adefolaju
MTMorrent Thang
Morrent Thang
LCLuz Andrea Cuaboy
Luz Andrea Cuaboy
CJCatherine John
Catherine John
SHShawn D. Hingtgen
Shawn D. Hingtgen
The lack of functional precision models that recapitulate the pathology and structure/function relationship of advanced ovarian cancer (OC) within an appropriate anatomic setting constitutes a hurdle on the path to developing more reliable therapies and matching those therapies with the right patients. Here, we developed and characterized an Organotypic Mesentery Membrane Culture (OMMC) model as a novel ex-vivo platform where freshly resected human patient OC tumor tissue or established cell lines are seeded directly atop living intact rat mesenteric membranes, rapidly engraft, and enable functional assessment of treatment response to FDA-approved standard care of treatment as single and combination drug therapies within just five days. This study showed successful survival of dissected mesentery tissue, survival and engraftment of tumor cells and patient tumor tissue seeded on OMMCs, mesentery-tumor cell interaction, and quantification of tumor response to treatment and off-target toxicity. Summarized “drug sensitivity scores”, using a multi-parametric algorithm, were also calculated for each patient’s treatment response, enabling us to suggest the most effective therapeutic option. Finally, we compared drug sensitivity results from patient tumor tissue on OMMCs to matched outcomes of individual patients in the clinic and identified positive correlations in drug sensitivity, beginning to validate the functionality of OMMCs as a functional predictor of treatment response. Summary sentence We have successfully developed and characterized a novel ex-vivo platform for personalized treatment of metastatic ovarian cancer.